Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

In the past, Dr. Horowitz had been a paid consultant for Purple Biotech.

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. | Novartis has finally given up on iscalimab after deciding that the ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025.

SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

Immunopathologies encompass a range of conditions known for their defined pathophysiology but lack safe and effective treatment options. These diseases ...

A mathematical model suggests that existing HPA-targeting drugs failed in clinical trials for mood disorders because the ...